| Filed On | Filing |
|---|---|
| 14 Oct 2026 |
8-K: Other Events
On October 14, 2026, Coya Therapeutics, Inc. (the “Company”) issued a press release announcing plans to initiate an open-label extension (“OLE”) of the Phase 2/3 ALSTARS Trial (NCT07161999) evaluating COYA 302 for the treatment of amyotr... |
| 05 Oct 2026 |
8-K: Other Events
On October 5, 2026, Coya Therapeutics, Inc. (the “Company”) issued a press release announcing full enrollment of the planned one hundred and twenty (120) patients in the Company’s ongoing Phase 2/3 ALSTARS Trial (NCT07161999) evaluating ... |
| 15 Sep 2026 |
8-K: Other Events
On September 15, 2026, Coya Therapeutics, Inc. (the “Company”) issued a press release announcing that the one hundredth (100th) patient has been enrolled in the Company’s ongoing Phase 2/3 ALSTARS Trial (NCT07161999) evaluating COYA 302,... |
| 11 Aug 2026 | 10-Q |
| 11 Aug 2026 | 8-K: Results of Operations and Financial Condition |
| 07 Aug 2026 |
8-K/A: Departure/Election of Directors or Officers; Compensation
This Amendment No. 1 to Current Report on Form 8-K/A (the “Amendment”) amends the Current Report on Form 8-K of Coya Therapeutics, Inc. (the “Company”) dated March 29, 2026 and filed with the Securities and Exchange Commission on April 2... |
| 27 Jul 2026 | SCHEDULE 13G/A |
| 25 Jun 2026 | 8-K: Submission of Matters to a Vote of Security Holders |
| 13 May 2026 | ARS |
| 13 May 2026 | DEFA14A |
| 13 May 2026 | Proxy statement: annual meeting on June 25, 2026 |
| 12 May 2026 | 424B5 |
| 12 May 2026 | 8-K: Entry into a Material Definitive Agreement |
| 12 May 2026 | 10-Q |
| 12 May 2026 | 8-K: Results of Operations and Financial Condition; Other Events |
| 09 Apr 2026 |
Form 4: Pavao Mark H, Director
Granted 10,000 Stock Option (right to buy) |
| 09 Apr 2026 |
Form 3: Pavao Mark H, Director
No securities owned |
| 02 Apr 2026 | 8-K: Departure/Election of Directors or Officers; Compensation |
| 20 Mar 2026 | EFFECT |
| 20 Mar 2026 | 424B3 |
Loading...
